Safety and Tolerability of Levomilnacipran ER in Major Depressive Disorder: Results from an Open-Label, 48-Week Extension Study

BACKGROUND: Levomilnacipran (1S, 2R-milnacipran) is a potent and selective serotonin (5-HT) and norepinephrine (noradrenaline) reuptake inhibitor approved for the treatment of major depressive disorder in adults. OBJECTIVE: The objective of this study was to evaluate the longer-term safety and toler...

Descripción completa

Detalles Bibliográficos
Autores principales: Mago, Rajnish, Forero, Giovanna, Greenberg, William M., Gommoll, Carl, Chen, Changzheng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2013
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3775192/
https://www.ncbi.nlm.nih.gov/pubmed/23999912
http://dx.doi.org/10.1007/s40261-013-0126-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3775192/
https://www.ncbi.nlm.nih.gov/pubmed/23999912
http://dx.doi.org/10.1007/s40261-013-0126-5

Ejemplares similares